One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequency ablation.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
47 patients (12 EUS-RFA, 35 controls), median survival was 13.
I · Intervention 중재 / 시술
EUS-RFA (January 2017 to September 2022) was compared with controls
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] EUS-RFA as an adjunct for UPDAC ≤4 cm may improve survival with minimal side effects. (Trial registration: The study was a secondary exploratory analysis of a clinical trial registered at Thai Clinical Trials Registry (https://www.thaiclinicaltrials.org/show/TCTR20180706001) with clinical trial number 20180706001.).
ℹ️ 이 논문은 무료 전문이 아직 없습니다. 코퍼스 전체의 43.9%는 무료 가능 (통계 →) · 🏥 기관 EZproxy로 시도
[BACKGROUND AND AIMS] The prognosis for unresectable pancreatic ductal adenocarcinoma (UPDAC) remains poor with current treatments.
- p-value P = .03
- p-value P = .04
APA
Kongkam P, Tantitanawat K, et al. (2025). One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequency ablation.. Gastrointestinal endoscopy, 102(6), 883-887. https://doi.org/10.1016/j.gie.2025.06.008
MLA
Kongkam P, et al.. "One-year survival rate of unresectable pancreatic cancer size 4 cm or smaller treated with or without EUS-radiofrequency ablation.." Gastrointestinal endoscopy, vol. 102, no. 6, 2025, pp. 883-887.
PMID
40680897 ↗
Abstract 한글 요약
[BACKGROUND AND AIMS] The prognosis for unresectable pancreatic ductal adenocarcinoma (UPDAC) remains poor with current treatments. This study evaluates the survival benefits of EUS-guided radiofrequency ablation (RFA) in UPDAC ≤4 cm.
[METHODS] A prospective series of patients who underwent EUS-RFA (January 2017 to September 2022) was compared with controls. Propensity score matching was applied using tumor size, staging, age-adjusted Charlson Comorbidity Index, and chemotherapy regimen. Inverse probability weighting was used to estimate treatment effects on survival, local progression, and response rates.
[RESULTS] Among 47 patients (12 EUS-RFA, 35 controls), median survival was 13.4 months in the EUS-RFA group versus 7.7 months for controls (hazard ratio, 0.50; P = .03). The survival probability at 12 months was 58% in the EUS-RFA group versus 22% for controls (P = .04). Adverse events were mild abdominal pain in 10% of RFA operations.
[CONCLUSIONS] EUS-RFA as an adjunct for UPDAC ≤4 cm may improve survival with minimal side effects. (Trial registration: The study was a secondary exploratory analysis of a clinical trial registered at Thai Clinical Trials Registry (https://www.thaiclinicaltrials.org/show/TCTR20180706001) with clinical trial number 20180706001.).
[METHODS] A prospective series of patients who underwent EUS-RFA (January 2017 to September 2022) was compared with controls. Propensity score matching was applied using tumor size, staging, age-adjusted Charlson Comorbidity Index, and chemotherapy regimen. Inverse probability weighting was used to estimate treatment effects on survival, local progression, and response rates.
[RESULTS] Among 47 patients (12 EUS-RFA, 35 controls), median survival was 13.4 months in the EUS-RFA group versus 7.7 months for controls (hazard ratio, 0.50; P = .03). The survival probability at 12 months was 58% in the EUS-RFA group versus 22% for controls (P = .04). Adverse events were mild abdominal pain in 10% of RFA operations.
[CONCLUSIONS] EUS-RFA as an adjunct for UPDAC ≤4 cm may improve survival with minimal side effects. (Trial registration: The study was a secondary exploratory analysis of a clinical trial registered at Thai Clinical Trials Registry (https://www.thaiclinicaltrials.org/show/TCTR20180706001) with clinical trial number 20180706001.).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
- Early local immune activation following intra-operative radiotherapy in human breast tissue.